JP2020519589A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519589A5
JP2020519589A5 JP2019561278A JP2019561278A JP2020519589A5 JP 2020519589 A5 JP2020519589 A5 JP 2020519589A5 JP 2019561278 A JP2019561278 A JP 2019561278A JP 2019561278 A JP2019561278 A JP 2019561278A JP 2020519589 A5 JP2020519589 A5 JP 2020519589A5
Authority
JP
Japan
Prior art keywords
chloro
quinazoline
oxazepino
tetrahydropyrazino
prop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019561278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/061787 external-priority patent/WO2018206539A1/en
Publication of JP2020519589A publication Critical patent/JP2020519589A/ja
Publication of JP2020519589A5 publication Critical patent/JP2020519589A5/ja
Withdrawn legal-status Critical Current

Links

JP2019561278A 2017-05-11 2018-05-08 G12c変異型rasタンパク質を阻害するヘテロアリール化合物 Withdrawn JP2020519589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504638P 2017-05-11 2017-05-11
US62/504,638 2017-05-11
PCT/EP2018/061787 WO2018206539A1 (en) 2017-05-11 2018-05-08 Heteroaryl compounds that inhibit g12c mutant ras proteins

Publications (2)

Publication Number Publication Date
JP2020519589A JP2020519589A (ja) 2020-07-02
JP2020519589A5 true JP2020519589A5 (https=) 2021-06-17

Family

ID=62492577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561278A Withdrawn JP2020519589A (ja) 2017-05-11 2018-05-08 G12c変異型rasタンパク質を阻害するヘテロアリール化合物

Country Status (8)

Country Link
US (2) US20200109153A1 (https=)
EP (1) EP3621968A1 (https=)
JP (1) JP2020519589A (https=)
CN (1) CN110603258A (https=)
AR (1) AR111776A1 (https=)
CA (1) CA3061650A1 (https=)
TW (1) TW201906848A (https=)
WO (1) WO2018206539A1 (https=)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453667B2 (en) 2018-01-19 2022-09-27 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
WO2020165732A1 (en) 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
ES3010507T3 (en) 2019-03-05 2025-04-03 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
US20220251109A1 (en) * 2019-04-28 2022-08-11 Genfleet Therapeutics (Shanghai) Inc. Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof
CN113993860B (zh) * 2019-06-25 2023-08-01 正大天晴药业集团股份有限公司 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
TW202115089A (zh) * 2019-07-01 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 喹唑啉酮類衍生物、其製備方法及其在醫藥上的應用
MX2022001421A (es) * 2019-08-02 2022-06-08 Shanghai Jemincare Pharmaceuticals Co Ltd Compuesto tetracíclico, método de preparación y uso del mismo.
CN112390818B (zh) * 2019-08-12 2023-08-22 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CA3155066A1 (en) * 2019-09-20 2021-03-25 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021058018A1 (en) * 2019-09-29 2021-04-01 Beigene, Ltd. Inhibitors of kras g12c
WO2021063346A1 (zh) * 2019-09-30 2021-04-08 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
CN112745335B (zh) * 2019-10-30 2024-08-30 武汉誉祥医药科技有限公司 一种三并杂环化合物及其用途
HRP20251479T1 (hr) 2019-11-01 2026-01-02 Syngenta Crop Protection Ag Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
EP4065231A1 (en) * 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
ES2929700T3 (es) 2019-12-11 2022-12-01 Lilly Co Eli Inhibidores de KRas g12c
CN111039845A (zh) * 2019-12-18 2020-04-21 大连奇凯医药科技有限公司 一种4-氟-7-溴靛红的制备方法
WO2021121371A1 (zh) * 2019-12-19 2021-06-24 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
GB202001344D0 (en) 2020-01-31 2020-03-18 Redx Pharma Plc Ras Inhibitors
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
AU2021248363B2 (en) * 2020-04-03 2024-02-15 Medshine Discovery Inc. Octahydropyrazinodiazanaphthyridine dione compounds
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物,其製法與醫藥上的用途
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
CN114075219B (zh) * 2020-08-14 2023-11-14 江苏恒瑞医药股份有限公司 喹啉稠环类衍生物、其制备方法及其在医药上的应用
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2021347232A1 (en) 2020-09-23 2023-04-27 Erasca, Inc. Tricyclic pyridones and pyrimidones
TWI880049B (zh) 2020-12-04 2025-04-11 美商美國禮來大藥廠 Kras g12c抑制劑
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685531B (zh) * 2020-12-25 2024-10-22 武汉誉祥医药科技有限公司 四并环化合物及其药物组合物和应用
CA3210167A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
WO2022188729A1 (en) * 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
EP4310091A4 (en) * 2021-03-17 2025-04-16 Genfleet Therapeutics (Shanghai) Inc. Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022216762A1 (en) * 2021-04-08 2022-10-13 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
CN117255793A (zh) 2021-06-21 2023-12-19 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
US20240294517A1 (en) 2021-06-24 2024-09-05 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
KR20240029051A (ko) * 2021-07-02 2024-03-05 상하이 드 노보 파마테크 컴퍼니 리미티드 Kras g12d 억제제 및 이의 용도
CN117677624A (zh) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JP2024534526A (ja) 2021-09-22 2024-09-20 四川匯宇制葯股▲フン▼有限公司 ピリジン系誘導体及びその使用
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023066371A1 (zh) * 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
TW202325298A (zh) * 2021-11-01 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4486345A1 (en) 2022-03-04 2025-01-08 Eli Lilly and Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
KR20240163107A (ko) 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
TW202400170A (zh) * 2022-05-19 2024-01-01 美商建南德克公司 氮雜-四環氧氮呯化合物及其用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN119421880A (zh) 2022-06-21 2025-02-11 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族化合物
MA71388A (fr) * 2022-07-05 2025-04-30 Pfizer Inc. Composés pyrido[4,3-d]pyrimidines
TW202408536A (zh) * 2022-07-29 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 一種包含kras g12d抑制劑的醫藥組成物
CA3261681A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
TW202416982A (zh) * 2022-08-11 2024-05-01 英屬開曼群島商百濟神州有限公司 雜環化合物、其組成物及用其進行治療之方法
AU2023320914A1 (en) * 2022-08-11 2025-02-27 Beone Medicines I Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
CN119768409A (zh) * 2022-08-25 2025-04-04 北京加科思新药研发有限公司 K-Ras突变蛋白抑制剂
GB202212641D0 (en) 2022-08-31 2022-10-12 Jazz Pharmaceuticals Ireland Ltd Novel compounds
WO2024051721A1 (en) * 2022-09-07 2024-03-14 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
WO2024138486A1 (en) * 2022-12-29 2024-07-04 Nikang Therapeutics, Inc. Tetracyclic derivatives as kras inhibitors
JP2025535294A (ja) * 2022-10-18 2025-10-24 アイディーエンス カンパニー リミテッド 新規なトリヘテロ環化合物
JP2026504244A (ja) 2022-11-09 2026-02-04 レヴォリューション・メディスンズ,インコーポレイテッド 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法
CN115583937B (zh) * 2022-11-21 2023-05-02 北京志道生物科技有限公司 以吲哚或氮杂吲哚为母核的kras抑制剂及其制备方法
WO2024110554A1 (en) 2022-11-23 2024-05-30 Syngenta Crop Protection Ag N-[(1 -[2-[6-(pyridazin-3-yl]-1,2,4-triazol-3-yl]ethyl]-quinazolin-4-amine and n-[1-[3-(6-(pyridazin-3-yl)pyrazin-2-yl]ethyl]-8-quinazolin-4-amine derivatives as pesticides
WO2024120419A1 (en) * 2022-12-06 2024-06-13 Zai Lab (Shanghai) Co., Ltd. Fused tetracyclic compounds as kras g12d modulators and uses thereof
KR20250120376A (ko) * 2022-12-07 2025-08-08 자코바이오 파마슈티칼스 컴퍼니 리미티드 축합환 화합물 및 이의 응용
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024153119A1 (en) * 2023-01-18 2024-07-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2024197503A1 (en) * 2023-03-27 2024-10-03 Nikang Therapeutics , Inc. Tricyclic derivatives as kras inhibitors
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
EP4700027A1 (en) * 2023-04-21 2026-02-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of nitrogen-containing tetracyclic compound and preparation method therefor
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024230734A1 (en) * 2023-05-08 2024-11-14 Jacobio Pharmaceuticals Co., Ltd. K-ras inhibitors and use thereof
WO2024243186A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Heterocyclic compounds as nras inhibitors
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2024248123A1 (ja) 2023-06-02 2024-12-05 第一三共株式会社 抗her3抗体-薬物コンジュゲートとrasg12c阻害剤の組み合わせ
AU2024307234A1 (en) 2023-06-30 2026-01-29 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025022007A1 (en) 2023-07-27 2025-01-30 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025022008A1 (en) 2023-07-27 2025-01-30 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (en) * 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025132349A1 (en) 2023-12-19 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025132754A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4691041B2 (ja) * 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Gtpアーゼ阻害剤および使用方法
WO2011121350A1 (en) * 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
ES2826443T3 (es) * 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
EP3356354A1 (en) * 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins

Similar Documents

Publication Publication Date Title
JP2020519589A5 (https=)
TWI579284B (zh) 咪唑并吡咯啶酮化合物
CN103096718B (zh) 可溶性鸟苷酸环化酶活化剂
JP2024502886A (ja) がんを処置及び/又は予防するためのsos1阻害薬の医薬組合せ
CN104080787B (zh) 吡唑并吡咯烷化合物
JP5199882B2 (ja) 高−増殖性障害及び脈管形成と関連する疾患の処置のために有用な置換4−アミノ−ピロロトリアジン誘導体
EP2968360B1 (en) Quinolinone derivatives for the inhibition of bromodomain-containing proteins
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
EP2958923A1 (de) 4-substituierte pyrrolo- und pyrazolo-diazepine
JP2005504080A5 (https=)
JP2009535295A (ja) キナーゼ阻害剤として有用なピロロトリアジンアニリンプロドラッグ化合物
JPWO2007126128A1 (ja) ジヒドロピラゾロピリミジノン誘導体
JP2012501327A5 (https=)
RU2007130153A (ru) Амидные производные
WO2016064957A1 (en) Bicyclic heteroaryl amine compounds as pi3k inhibitors
CN111386114A (zh) 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
KR20130102060A (ko) 퀴나졸린 화합물 및 이의 사용 방법
KR20140037195A (ko) 신규 프탈라지논-피롤로피리미딘카복스아미드 유도체
JP2009500366A5 (https=)
JPWO2001083460A1 (ja) 環状化合物